Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

UGT polymorphisms and lamotrigine clearance during pregnancy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Pharmacodynamics of remifentanil. Induced intracranial spike activity in mesial temporal lobe epilepsy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Maternal and fetal outcomes associated with vagus nerve stimulation during pregnancy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Dynamics of muscle activation during tonic-clonic seizures

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Alternative diets to the classical ketogenic diet-Can we be more liberal?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. No effect of oral contraceptives on the metabolism of levetiracetam

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Anomalies of imagination in the schizophrenia-spectrum: Empirical findings

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  2. Electromagnetic source imaging in presurgical workup of patients with epilepsy: A prospective study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVE: To evaluate the impact of maternal UGT1A4 and UGT2B7 genetic polymorphisms and sex of foetus on gestation-induced changes in lamotrigine (LTG) clearance during pregnancy and post-partum (PP).

METHODS: Single nucleotide polymorphisms UGT1A4 142T > G, L48V (*3), UGT1A4 70C > A, P24T (*2) and UGT2B7 802C > T, H268Y (*2) were determined in 40 women (47 pregnancies) with epilepsy treated with LTG. Retrospectively collected data included LTG dosage and LTG plasma levels before pregnancy (T0), and LTG dosage and LTG plasma level changes in the first (T1), second (T2) and third trimester (T3), and post-partum (PP) as well as the sex of the foetus.

RESULTS: Reductions in the LTG concentration-to-dose ratio (C/D ratio) during pregnancy were seen in all genotype panels and varied between -53% and -74% in T3. Genetic polymorphism of UGT1A4 T142G (*3) and UGT2B7 C802T (*2) had the most pronounced influence on LTG clearance. Women with UGT1A4 142TG had a lower decrease in the C/D ratio in T3 than those with wild type: -53% (95%CI: -68% to -39%) versus -65% (95%CI: -69% to -60%) (p = 0.04). In homozygous carriers of UGT2B7 802TT the LTG C/D ratio was reduced significantly already in T1 (p = 0.015) as well as in T3 compared to the heterozygous carriers (802CT) (p = 0.04). Multiple regression analysis demonstrated that women who carried a female foetus had a significantly higher reductions in the LTG C/D ratio from T0 to the end of pregnancy than those with a male foetus (p = 0.003). In the univariate analysis the reductions in LTG C/D ratio were -64% in T2 (95%CI: -69% to -59%) and -67% in T3 (95%CI: -71% to -63%) in women who expected a female child compared to whose with a male child -58% in T2 (p = 0.002, 95%CI: -67% to -48%) and -57% in T3 (p < 0.001, 95%CI: -65% to -48%).

CONCLUSION: Genetic polymorphism in UGT1A4 and UGT2B7 may play a modest role in LTG clearance changes during pregnancy. In addition, our study indicates that the sex of the foetus influenced significantly the change in LTG clearance.

OriginalsprogEngelsk
TidsskriftEpilepsy Research
Vol/bind140
Sider (fra-til)199-208
ISSN0920-1211
DOI
StatusUdgivet - 2018

ID: 52751712